CGNI Share Price Performance
UK£0.07
-0.53 (-88.33%)
Price UK£0.07
Share Pricen/a
Cardiogeni PLC Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
CGNI Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Cardiogeni PLC Key Details
About CGNI
- Founded
- 2007
- Employees
- 3
- CEO
- WebsiteView website
Cardiogeni PLC, a clinical stage biotechnology company, develops heart failure medicines. Its lead product is CLXR-001, a patented engineered cellular medicine, which has completed Phase II clinical trial to treat heart failure patients during coronary artery bypass grafting surgery. The company also develops CLXR-002 and CLXR-003 for heart failure with minimally invasive delivery; and CLXR-004 for use in combination with LVAD device to treat sever heart failure orphan disease indication. The company was founded in 2007 and is headquartered in Stratford-upon-Avon, the United Kingdom.
